CUMYL-NBMICA
Synthetic indole-3-carboxamide cannabinoid, full CB1 agonist, French legal status uncertain.
C₂₆H₃₀N₂O
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- 1-(2-bicyclo[2.2.1]heptanylmethyl)-N-(2-phenylpropan-2-yl)indole-3-carboxamide
- Other names
- VH7ZT48Y4P
Identifiers
- Formula
- C₂₆H₃₀N₂O
- Molar mass
- 386.50 g/mol
- PubChem CID
- 168319301(new tab)
- InChIKey
- BANLFAZSVPLZEB-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
Updated on
Receptors and activity
- CB1Agonist91 out of 100
Ki compris entre 0,25 et 1,87 nM pour les trois SCRA à chaîne norbornylméthyle (Pulver et coll., 2023) ; valeur propre à ce composé non donnée dans le résumé publié
Subjective signature
- Calm
- 10 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 5 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 15 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 15 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 10 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
CUMYL-NBMICA is a synthetic indole-3-carboxamide and a full CB1 receptor agonist according to Pulver et al. (2023). It belongs to three norbornylmethyl SCRAs whose Ki values lie between 0.25 and 1.87 nM, although the published abstract does not give the value specific to this compound. Described in 2021 from seizures, including a pure powder, it has no clinical or toxicological study in humans. The sources consulted come from in vitro pharmacology and forensic analysis, and the question of its French legal status remains open.
Key sources.
- Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des agonistes à chaînes cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023 (new tab)PMID 36541839
- Pulver et coll., jeu de données d'identification de trois SCRA à chaîne norbornylméthyle, Data in Brief, 2021 (new tab)PMID 34988267
- Giorgetti et coll., métabolisme de phase I chez l'humain du Cumyl-CBMEGACLONE, du Cumyl-NBMEGACLONE et du Cumyl-NBMINACA, Drug Test Anal, 2025 (new tab)PMID 39218806
- ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (new tab)
- INCB, Liste verte 2026 (tableaux de la Convention de 1971) (new tab)
- PubChem, CUMYL-NBMICA, CID 168319301 (new tab)
History
- Source
- An entirely synthetic molecule, absent from cannabis and from any other plant. It belongs to the norbornylmethyl-side-chain SCRAs that reached the drug market between 2019 and 2021, a series described as having circumvented German legislation. This compound was seized as a pure powder, whereas two other members of the series were found mixed with plant products.
Origin (pharmaceutical research → illicit market)
No known biosynthetic pathway: a synthetic molecule belonging to the indole-3-carboxamide class.
Legal framework
- European Union
No harmonised control measure at European Union level was identified in the sources consulted: control falls to Member States. In Germany, the 2020 revision of the new psychoactive substances act scheduled the cyclobutylmethyl SCRAs, while the norbornylmethyl derivatives, of which this compound is one, were detected after that revision.
- France
In France, this compound is not named on the consolidated list of narcotics updated on 16 February 2026 by ANSM. Whether it falls under the generic definition of 3-carboxamide indoles in annex IV of the amended order of 22 February 1990 is not established with certainty: the amide condition is met, since the amide nitrogen carries a cumyl group, but the definition lists bicyclo[2.2.1]heptanyl only among the substituents of the amide nitrogen, not among those of the indole nitrogen, where it retains cycloalkylmethyl without mentioning bicyclic groups. The French status therefore remains uncertain until an ANSM decision names this compound.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des agonistes à chaînes cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023 (new tab)PMID 36541839
- Pulver et coll., jeu de données d'identification de trois SCRA à chaîne norbornylméthyle, Data in Brief, 2021 (new tab)PMID 34988267
- Giorgetti et coll., métabolisme de phase I chez l'humain du Cumyl-CBMEGACLONE, du Cumyl-NBMEGACLONE et du Cumyl-NBMINACA, Drug Test Anal, 2025 (new tab)PMID 39218806
- ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (new tab)
- INCB, Liste verte 2026 (tableaux de la Convention de 1971) (new tab)
- PubChem, CUMYL-NBMICA, CID 168319301 (new tab)
Structured data
- SMILES
- CC(C)(C1=CC=CC=C1)NC(=O)C2=CN(C3=CC=CC=C32)CC4CC5CCC4C5
- InChIKey
- BANLFAZSVPLZEB-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.